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Edited by Stuart FergusonAbstract Human kallikrein 8 (KLK8) is a member of the hu-
man kallikrein gene family of serine proteases, and its protein,
hK8, has recently been suggested to serve as a new ovarian can-
cer marker. To gain insights into the physiological role of hK8,
the active recombinant enzyme was obtained in a pure state for
biochemical and enzymatic characterizations. hK8 had trypsin-
like activity with a strong preference for Arg over Lys in the
P1 position, and its activity was inhibited by typical serine pro-
tease inhibitors. The protease degraded casein, ﬁbronectin, gela-
tin, collagen type IV, ﬁbrinogen, and high-molecular-weight
kininogen. hK8 also converted human single-chain tissue-type
plasminogen activator (65 kDa) to its two-chain form (32 and
33 kDa) by speciﬁcally cleaving the peptide bond Arg275–Ile276.
This conversion resulted in a drastic increase in the activity of
the activator toward the ﬂuorogenic substrate Pyr-Gly-Arg-
MCA and plasminogen in the absence of ﬁbrin. Our ﬁndings sug-
gest that hK8 may be implicated in ECM protein degradation in
the area surrounding hK8-producing cells.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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activator1. Introduction
The tissue kallikreins are a subgroup of trypsin- and chymo-
trypsin-like serine proteases that are characterized by their
homology to true tissue kallikrein, which is encoded by
KLK1/Klk1 gene in many species. These proteases share a high
degree of sequence and structural similarity [1–3].
In recent studies, at least 15 genes encoding serine proteases
have been identiﬁed in the human glandular kallikrein locus on
chromosome 19q13.3–q13.4 [4–6]. Detailed mapping of the hu-
man kallikrein gene locus revealed that KLK4-14 are located
telomeric to KLK2, which encodes human glandular kallikrein
2 (hK2), while KLK15 is located between KLK1, which en-
codes classical tissue kallikrein, and KLK3, which encodes
prostate-speciﬁc antigen (PSA) [7]. Twelve of these ﬁfteen
KLK genes – i.e., all but KLK1-3 – were discovered in recent
years. Existing evidence suggests that all of the new KLK genes
encode functional proteins. However, our knowledge of the*Corresponding author. Fax: +81 11 706 4851.
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doi:10.1016/j.febslet.2005.11.039KLK gene products is very limited at present. The chemical
identities and molecular properties of human kallikrein 6
(hK6) [8–10], and, more recently, hK13 [11] and hK5 [12] have
been determined.
KLK8 (also known as neuropsin/ovasin) was cloned from a
human skin cDNA library as a homologue of mouse neuropsin
[13]. In the mouse, KLK8 mRNA is localized at high concen-
tration in the skin and brain, and the gene product has been
shown to play an important role in normal hippocampal func-
tion [14]. KLK8 mRNA was also detected in the hippocampus
of normal human brains. Interestingly, the KLK8 transcript
level in the hippocampus of patients with Alzheimers disease
was found to be elevated 11.5-fold compared to that in con-
trols, suggesting that KLK8 may play a role in neurodegener-
ation [15]. Furthermore, human KLK8 mRNA and its
protein (hK8) have been shown to be more highly expressed
in ovarian cancer tissues than in normal ovarian tissue
[16,17]. These ﬁndings led to the proposal that hK8 protein
may serve as a new ovarian cancer marker [17,18]. However,
despite the increasing biological and clinical interest in hK8,
there have been no reports describing the biochemical and
enzymatic properties of this protein. In the present study, ac-
tive recombinant hK8 was produced and characterized. The
present data indicate that hK8 is a trypsin-like enzyme that de-
grades some extracellular matrix (ECM) proteins, such as col-
lagen type IV and ﬁbronectin. The enzyme is also capable of
converting single-chain tissue-type plasminogen activator
(tPA) to its two-chain protein. These results suggest that
hK8 plays a role in the turnover of ECM proteins.2. Methods
2.1. hK8 expression vector construction
The expression vectors for hK8 were constructed by inserting its
cDNA (DDBJ/EMBL/GenBank databases AB009849) including the
mature enzyme region (amino acids 33–260) with an enteropeptidase
cleavage site at the 5 0 end into the KpnI and EcoRI sites of pET30a.
To amplify the insert, two oligonucleotide primers were synthesized:
the sense primer 5 0-CGGGGTACCGACGACGACGACAAGGT-
GCTGGGGGGTCAT-3 0, which contained the KpnI site, the entero-
peptidase susceptibility site DDDDK, and the 5 NH2-terminal residues
(Val33 to His37) of mature hK8, and the antisense primer 5 0-CCG-
GAATTCTCAGCCCTTGCTGCC-3 0, which included the EcoRI site
and the 4 COOH-terminal residues (Gly257–Gly260) of the mature en-
zyme. PCR was performed with KOD plus DNA polymerase (Toyobo,
Osaka, Japan) using human adult ovary total RNA (Stratagene, La
Jolla, CA) as a template. The PCR conditions were 3 min at 94 C
for heating, followed by 30 cycles of 30 s at 94 C for denaturing,ation of European Biochemical Societies.
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tion product was sequentially digested with KpnI and EcoRI, gel puri-
ﬁed and ligated in frame between the KpnI and EcoRI sites of pET30a.
The orientation and sequence of the cDNA in the vector (pET30a-
hK8) were conﬁrmed by DNA sequencing.
2.2. Preparation of active recombinant hK8
The ligated vector (pET30a-hK8) was transformed to E. coli strain
BL21. The cells were grown at 37 C, induced with isopropyl-1-thio-
b-D-galactoside. Cells were harvested by centrifugation and lysed by
freeze–thawing. The materials were washed twice with 0.5% Triton
X-100 and solubilized by being dissolved and then incubated in
50 mM Tris–HCl (pH 7.8) containing 6 M urea and 0.5 M NaCl for
12 h at room temperature. The solubilized materials were directly ap-
plied to a Ni2+-chelate column (5 ml volume) (Novagen, Madison,
WI) previously equilibrated with 50 mM Tris–HCl (pH 7.8) containing
0.5 M NaCl and 6 M urea. The column was washed extensively with
the above buﬀer containing 20 mM imidazole (100 ml), and then eluted
with 50 mM histidine in the same buﬀer containing 0.5 M NaCl and
6 M urea. Eluted proteins were dialyzed against 50 mM Tris–HCl
(pH 8.0) and stored at 20 C.
The enzymatically inactive fusion protein thus produced was acti-
vated with recombinant enteropeptidase from the medaka ﬁsh (Oryzias
latipes), a small freshwater teleost. Medaka enteropeptidase was immo-
bilized on CNBr-activated Sepharose 4B (Sigma, St. Louis, MO) prior
to use according to the manufacturers protocol. hK8 was incubated
with the immobilized enteropeptidase for 16 h at room temperature.
After removing the immobilized protease by ﬁltration, the activity of
hK8 was assayed by a 4-methylcoumaryl-7-amide (MCA)-containing
synthetic substrate, Pro-Phe-Arg-MCA (Peptide Institute, Osaka, Ja-
pan). The molecular cloning, expression, and characterization of me-
daka enteropeptidase will be reported elsewhere.
2.3. Enzyme activity assay
Unless otherwise stated, hK8 activity was determined at 37 C with
Pro-Phe-Arg-MCA according to the method of Barrett [19], with the
slight modiﬁcations reported in our previous study [20]. The release
of ﬂuorophore 7-amino-4-methyl coumarin (AMC) was measured by
spectroﬂuorometry using an excitation wavelength of 370 nm and an
emission wavelength of 460 nm.
Active hK8 was preincubated with various protease inhibitors at
37 C in 0.1 M Tris–HCl buﬀer (pH 8.0). After incubation for
15 min, enzyme activity was measured using Pro-Phe-Arg-MCA as
substrate.2.4. Kinetic parameters
Kinetic parameters were determined for various MCA substrates.
Initial velocities, extrapolated from the plot of product versus time,
were transformed into double-reciprocal plots [21]. Maximum veloci-
ties (Vmax), Km, and kcat values were obtained from the intercepts of
these plots.
The active rhK8 concentration was determined using the active site
titrant p-nitrophenyl-p 0-guanidinobenzoate HCl [22].Fig. 1. Purity of puriﬁed recombinant hK8. Puriﬁed hK8 was
subjected to SDS–PAGE analysis under reducing conditions and
visualized by Coomassie Brilliant Blue R-250 staining. Lane 1,
molecular weight marker (kDa); lane 2, hK8 fusion protein; lane 3,
active hK8.2.5. Digestion of protein substrates
Forty micrograms of human plasma ﬁbronectin (Chemicon, Teme-
cula, CA), porcine type 1 gelatin (Daiichi Fine Chemicals, Toyama, Ja-
pan), mouse laminin (Biomedical Technologies Inc., Stoughton, MA),
human ﬁbrinogen (Merk Biosciences, Tokyo, Japan), human high-
molecular-weight kininogen (Calbiochem), and casein (Sigma) were
incubated at 37 C in 200 ll of 50 mM Tris–HCl buﬀer (pH 8.0) with
4 lg of hK8. Aliquots of 20 ll mixtures were taken at various time
points (0–18 h), and mixed with 5 ll of SDS–PAGE sample buﬀer.
The mixtures were boiled and aliquots of 20 ll samples were subjected
to SDS–PAGE under reducing conditions. After electrophoresis, gels
were stained with 0.25% Coomassie Brilliant Blue.
Twenty-ﬁve micrograms of FITC-conjugated bovine collagen type I
and type IV (Yagai Corporation, Yamagata, Japan) were incubated
with hK8 (0.25 lg) at 33 C for 16 h in 100 ll of 50 mM Tris–HCl buf-
fer (pH 8.0). After incubation, the reactions were terminated by adding
300 ll of stopping reagent (42% ethanol, 50 mM Tris–HCl (pH 9.5),
and 0.2 M NaCl). Samples were incubated on ice for 10 min, and then
centrifuged at 10000 · g for 10 min. Aliquots of the resulting superna-tants were diluted to a volume of 3.0 ml with distilled water, and the
ﬂuorescence was measured at an excitation wavelength of 459 nm
and an emission wavelength of 520 nm.
2.6. Conversion of single-chain tPA to two-chain tPA
Ten micrograms of recombinant human single-chain tPA (American
Diagnostica Inc., Greenwich, CT) were incubated at 37 C with active
hK8 (1 lg) in 200 ll of 0.1 M Tris–HCl buﬀer (pH 8.0). After incuba-
tion, 20 ll of the reaction mixture was incubated with aprotinin (2 lg)
for an additional 10 min at 37 C. The mixtures were then assayed for
the enzyme activity using Pyr-Gly-Arg-MCA as a substrate. This proce-
dure enabled the determination of two-chain tPA activity speciﬁcally.
Samples of human tPA treated with active hK8 were separated by
SDS–PAGE under reducing conditions, and transferred to polyvinyli-
dene diﬂuoride membrane (PVDF) (Millipore, Bedford, MA). The
blotted membrane was incubated with mouse anti-human tPA mono-
clonal antibody (Oncogene Research Products, San Diego, CA) at
1:500 dilution and subsequently with sheep anti-mouse IgG antibody
conjugated with horseradish peroxidase (Amersham Biosciences,
Buckinghamshire, England). Immunoreactive signals were detected
using an ECL Western blot detection kit (Amersham Biosciences).
2.7. Plasminogen activation
Ten micrograms of recombinant human plasminogen (Calbiochem)
was incubated at 37 C with sctPA (1 lg) in the presence or absence of
active hK8 (0.1 lg) in 200 ll of 0.1 M Tris–HCl buﬀer (pH 8.0). As
additional controls, plasminogen alone or hK8 alone was incubated.
After incubation, 20 ll of the reaction mixture was used for the enzyme
activity assay using the synthetic substrate Boc-Glu-Lys-Lys-MCA for
generated plasmin. Assays with MCA substrate were conducted as de-
scribed as above.3. Results
3.1. Substrate speciﬁcity of hK8
The recombinant protein was expressed in E. coli (BL21)
transformed with pET30a-hK8, and the enzyme was puriﬁed
as described in the methods. SDS–PAGE analysis of the puri-
ﬁed fusion hK8 protein showed a single band of 35.5 kDa un-
der reducing conditions (Fig. 1). Treatment of the protein with
immobilized medaka enteropeptidase successfully produced
active hK8 with a molecular mass of 31.5 kDa under the same
conditions (Fig. 1). Autocatalytic activation of the fusion pro-
tein was not observed.
Active recombinant hK8 was stable at 20 C; the initial en-
zyme activity was retained for at least two months with no
detectable change in the electrophoretic pattern.
Table 2
Eﬀects of protease inhibitors on hK8 activity
Inhibitor Concentration Inhibition (%)
DFP 2.0 mM 100
Antipain 0.2 mM 100
Aprotinin 0.01 mg/ml 98
Leupeptin 0.2 mM 95
SBTI 0.1 mg/ml 75
0.2 mg/ml 87
Benzamidine 0.2 mM 18
1.0 mM 83
E-64 0.5 mM 6
o-Phenanthroline 2.0 mM 7
Pepstatin 0.1 mM 0
TPCK 0.2 mM 3
TLCK 0.2 mM 8
DFP, diisopropyl ﬂuorophosphate; SBTI, soybean trypsin inhibitor;
TPCK,Na-p-tosyl-L-phenylalanine chloromethyl ketone; TLCK, Na-p-
tosyl-L-lysine chloromethyl ketone.
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range 7–10 in a typical bell shape, and the optimum pH was
found to be 8.5 (data not shown).
Fluorogenic peptide substrates having an MCA leaving
group were used to determine the kinetic parameters (Table
1). Among the substrates tested, Pro-Phe-Arg-MCA was the
best substrate for hK8 based on its kcat/Km value. Z-Val-Val-
Arg-MCA and Boc-Val-Pro-Arg-MCA were hydrolyzed by
the enzyme. hK8 detectably cleaved the substrates Boc-Leu-
Lys-Arg-MCA and Boc-Phe-Ser-Arg-MCA. The enzyme
reproducibly hydrolyzed a lysine-containing substrate Boc-
Val-Leu-Lys-MCA to a similar extent, whereas another avail-
able lysine-containing substrate Boc-Glu-Lys-Lys-MCA was
resistant to the enzyme hydrolysis. Generally, the Km values
were fairly constant with all the substrates tested, indicating
that diﬀerences in the catalytic eﬃciency of the enzyme (kcat/
Km) for individual substrates were largely due to the diﬀerences
in kcat values.
The substrates Suc-Leu-Leu-Val-Tyr-MCA, Suc-Ala-Ala-
Pro-Phe-MCA, and Ac-Ile-Glu-Thr-Asp-MCA were not
hydrolyzed by hK8 at all.
In short, hK8 is an enzyme with primary speciﬁcity for L-
arginine peptide bonds, and with marginal speciﬁcity for L-ly-
sine peptide bonds.
3.2. Eﬀects of inhibitors on hK8
The eﬀects of various protease inhibitors on amidolytic
activity of hK8 were examined using Pro-Phe-Arg-MCA as a
substrate (Table 2). The enzyme activity was strongly inhibited
by serine protease inhibitors, such as diisopropylﬂuorophos-
phate (DFP), antipain, aprotinin, leupeptin, benzamidine,
and soybean trypsin inhibitor (SBTI). No detectable inhibition
was observed with Na-p-tosyl-L-lysine chloromethyl ketone
(TLCK), Na-p-tosyl-L-phenylalanine chloromethyl ketone
(TPCK), pepstatin, o-phenanthroline, or E-64.
3.3. Digestion of protein substrates by hK8
Casein was extensively and rapidly degraded by hK8, yield-
ing a number of fragments with lower molecular masses
(Fig. 2A). Eﬃcient but rather speciﬁc proteolytic activity of
hK8 was found against human plasma ﬁbronectin (Fig. 2B).
The pattern of ﬁbronectin digestion by hK8 is apparently dif-
ferent from that of its murine counterpart [24], but similar to
that observed with murine Klk21 [20].
Gelatin type I was eﬃciently degraded by hK8 (Fig. 2C).
Collagen type I was resistant to the enzyme, while collagen
type IV was cleaved by hK8 (Fig. 2D).Table 1
Kinetic parameters of hK8 as measured on MCA-containing substrates
Substrates Vmax (lmol/min/mg) K
Pro-Phe-Arg-MCA 7.1 0
Z-Val-Val-Arg-MCA 5.4 0
Boc-Val-Pro-Arg-MC 3.9 0
Boc-Leu-Lys-Arg-MCA 2.6 0
Boc-Phe-Ser-Arg-MCA 1.6 0
Boc-Val-Leu-Lys-MCA 1.9 0
Boc-Glu-Lys-Lys-MCA ND\
Suc-Leu-Leu-Val-Tyr-MCA ND
Ac-Ile-Glu-Thr-Asp-MCA ND
Suc-Ala-Ala-Pro-Phe-MCA ND
ND\, not detected.Human kallikrein 8 could digest ﬁbrinogen by rapidly cleav-
ing the Bb chain, and slightly cleaving the Aa chain. However,
the c chain remained intact (Fig. 2E). This degradation pattern
was distinct from that of human thrombin; thrombin degraded
the Aa chain rapidly and the c chain slowly, while the Bb chain
was not degraded (data now shown).
High-molecular-weight kininogen was also a substrate of
hK8 (Fig. 2F).
3.4. Eﬀect of hK8 on single-chain tPA
Human single chain tPA, which has little or no activity as
assayed with the substrate Pyr-Gly-Arg-MCA, was activated
by human kallikrein 8 (Fig. 3A). The tPA activity increased
rapidly within the initial 2 h and then leveled oﬀ after 6 h. Wes-
tern blot analysis of the reaction mixtures indicated that the
activation underlies the production of two-chain tPA (33 and
32 kDa) from its single chain precursor molecule (65 kDa) in
a time-dependent manner with a ﬁxed amount of enzyme sam-
ple (Fig. 3B). Prolonged incubation resulted in no decline of
activated tPA activity, suggesting that hK8 activated tPA by
cleaving a speciﬁc peptide bond at the presumed activation site
with no further hydrolysis. In contrast, the tPA activity caused
by trypsin activation ﬁrst increased to a level comparable to
that observed with hK8 and declined thereafter (data not
shown). This was probably due to extensive hydrolysis of the
activated tPA by trypsin. These results indicate that proteolytic
cleavage at a single internal peptide bond underlies the activa-
tion of tPA by hK8. In order to determine the cleavage site, them (mM) kcat (min
1) kcat/Km (mM
1/min)
.07 180 2600
.07 140 2000
.07 98 1400
.10 65 650
.07 40 570
.10 48 480
Fig. 2. Action of hK8 on protein substrates. (A) SDS–PAGE of casein
incubated with hK8. Lane 1, molecular weight marker (kDa). Casein
was incubated with hK8 for 0 (lane 2), 1 (lane 3), 2 (lane 4), 4 (lane 5), 6
(lane 6), or 8 h (lane 7). The protein was incubated without hK8 for 1 h
(lane 8). (B) SDS–PAGE of ﬁbronectin incubated with hK8. Lane 1,
molecular weight marker; lane 2, ﬁbronectin incubated without (lane 2)
or with hK8 (lane 3) for 18 h. (C) SDS–PAGE of gelatin incubated
with hK8. gelatin incubated without (lane 1) or with hK8 (lane 2) for
18 h at 37 C. (D) Eﬀects on collagens type I and type IV. FITC-
conjugated collagens were incubated without (hK8) or with hK8
(+hK8) for 16 h, and the ﬂuorescence intensities of the supernatants
were measured. (E) SDS–PAGE of ﬁbrinogen incubated with hK8.
Lane 1, molecular weight marker (kDa). Fibrinogen was incubated
with hK8 for 0 (lane 2), 1 (lane 3), 2 (lane 4), 4 (lane 5), 6 (lane 6), or 8
h (lane 7). Fibrinogen alone (lane 8) or hK8 alone (lane 9) was
incubated for 1 h. Positions corresponding to polypeptides Aa, Bb,
and c of ﬁbrinogen are shown at right. (F) SDS–PAGE of high-
molecular-weight kininogen incubated with hK8. Lane 1, molecular
weight marker (kDa). High-molecular-weight kininogen was incubated
with hK8 for 0 (lane 2), 0.5 (lane 3), 1 (lane 4), 2 (lane 5), 4 (lane 6), or
6 h (lane 7). Lane 8, incubation for 6 h without hK8.
Fig. 3. Eﬀect of hK8 on tPA. (A) Human single-chain tPA was
incubated alone () or with hK8 () at 37 C. Aliquots of the
incubation mixture were taken at the indicated times, and the activity
of activated tPA toward Pyr-Gly-Arg-MCA was selectively determined
by assaying in the presence of aprotinin. As a control, incubations of
hK8 alone (m) were conducted. (B) Human single-chain tPA was
incubated with hK8 in the same buﬀer as in (A). Aliquots of the
incubation mixture were taken at 0 (lane 1), 0.5 (lane 2), 1 (lane 3), 2
(lane 4), 4 (lane 5), and 6 h (lane 6) and subjected to SDS–PAGE/
Western blot analysis under reducing conditions. The positions of
single-chain tPA (65 kDa) and tctPA (33 and 32 kDa) are indicated at
right. (C) Eﬀect of hK8 on plasmin generation in the tPA/plasmin
system. Plasminogen was incubated at 37 C with sctPA in the absence
or presence of hK8. Plasminogen alone or hK8 alone was incubated as
additional controls. Aliquots of the reaction mixtures were taken at the
indicated times for plasmin activity assay using Boc-Glu-Lys-Lys-
MCA. , plasminogen + single-chain tPA + hK8; , plasmino-
gen + single-chain tPA;m, plasminogen + hK8;h, plasminogen alone;
·, hK8 alone.
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lyzed. Two sets of sequences (Ile-Lys-Gly-Gly-Leu-Phe-Ala-
Glu- and Ser-Val-Gln-Val-Ile-X-Arg-Glu-) were obtained with
tPA treated with hK8 for 6 h. The former corresponds to the
internal sequence of sctPA (Ile276-Glu283), and the latter to
the NH2-terminal sequence (Ser
1-Glu8) [25]. These results
clearly indicate that the Arg275-Ile276 peptide bond in sctPA
was speciﬁcally cleaved by hK8.
hK8 had no eﬀect on plasminogen; incubation of plasmino-
gen with the enzyme for 6 h did not generate plasmin. SDS–
PAGE analysis of plasminogen incubated with hK8 showed
no degraded polypeptides (data not shown).
The generation of plasmin from plasminogen by single-chain
tPA was examined in the presence or absence of hK8. A rapid,
dramatic increase of the plasmin activity was observed whenplasminogen, single-chain tPA and hK8 were present in the
reaction mixture, while the activity increased slowly in the ab-
sence of hK8 (Fig. 3C). There was no detectable plasmin activ-
ity when plasminogen was incubated with hK8 only. The
presence of trace amounts of active tPA in the single-chain
tPA preparation probably led to the plasmin generation in
the incubation of plasminogen with only sctPA. These results
clearly indicate that the production of plasmin from plasmin-
ogen by tPA is detectably accelerated in the presence of hK8.4. Discussion
The present study provided the ﬁrst characterization of hK8
using recombinant protein. As expected, hK8 was demon-
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zyme primarily hydrolyzes MCA substrates containing Arg
at the P1 position. In addition, hK8 slightly hydrolyzed Boc-
Val-Leu-Lys-MCA, but not Boc-Glu-Lys-Lys-MCA. Regard-
ing the action of hK8 on the Lys-containing substrate, we
should note that a crystal structural study [26] on the mouse
homologue of hK8, neuropsin, revealed S1-pocket speciﬁcity
for both Arg and Lys due to the unique conformations of
the kallikrein loops G and H.
The present study demonstrated the ability of hK8 to hydro-
lyze a variety of protein substrates, suggesting its involvement
in various biological processes. Previous studies have estab-
lished that hK8 is detectable in various tissue extracts and bio-
logical ﬂuids, including breast milk, amniotic ﬂuid, seminal
plasma, and serum [27]. More interestingly, Kishi et al. re-
ported that hK8 protein expression is higher in ovarian cancer
tissue extracts, serum, and ascites ﬂuids, than in benign and
normal tissues [17]. They also suggested that hK8 is likely se-
creted by tumor cells in ovarian cancer. Another study re-
ported that the KLK8 gene was expressed more highly in
ovarian carcinomas than in normal ovarian tissue [16]. In this
context, it is of particular interest to note our present ﬁnding
that hK8 is capable of degrading ﬁbronectin and collagen type
IV. Fibronectin is an ECM protein that serves as a general
adhesive molecule, linking cells to one another or to other sub-
strates such as collagen and proteoglycans. Existing evidence
indicates that this adhesion protein is a major ECM compo-
nent expressed in the ovary [28]. Collagen type IV is a compo-
nent of the basement membrane. Generally, the degradation of
both ﬁbronectin and collagen type IV is thought to be a critical
step for cancer cells to invade and metastasize. These consider-
ations tempt us to speculate that hK8 may be involved in the
invasive and metastatic process of ovarian cancer cells.
Another interesting ﬁnding of the present study is that sin-
gle-chain tPA is a substrate of hK8. Speciﬁc cleavage at the
peptide bond Arg275-Ile276 in single-chain tPA by the enzyme
produced two-chain tPA. It has previously been shown that
single-chain tPA has only limited plasmin-producing activity
unless the cofactor ﬁbrin is present, whereas the two-chain
form of tPA itself exhibits full activity in the absence of ﬁbrin
[29]. Therefore, hK8 could initiate the operation of the tPA/
plasmin system in the absence of ﬁbrin. Indeed, our current
data indicate that the active serine protease plasmin was
promptly produced upon incubation of plasminogen with sin-
gle-chain tPA in the presence of active hK8. It is generally
agreed that plasmin catalyzes the degradation of proteins in
basement membranes and ECM and thus facilitates cancer cell
invasion into the surrounding tissue [30–32]. Since plasmino-
gen is abundantly present in the tissue ﬂuid, hK8 may trigger
activation of the tPA/plasmin system if cancer cells synthesize
and secrete both sctPA and hK8. It would be interesting to
examine whether this assumption is correct using ovarian can-
cer cells producing hK8 protein [17].
We found that hK8 degrades both ﬁbrinogen and HMW-
kininogen, but the biological signiﬁcance of this result is not
known at present.
We previously reported the presence of an enzyme capable
of converting single-chain tPA to two-chain tPA in the preovu-
latory human follicular ﬂuid [23]. Judging from its characteris-
tics, we assumed that the enzyme might be a tissue kallikrein.
Since we were unable to detect immunoreactive materials in
follicular ﬂuid by Western blotting using anti-hK8 antibodies(our unpublished observations), hK8 is not likely to be the en-
zyme responsible for the activation of single-chain tPA in fol-
licular ﬂuid.
In conclusion, the present report provides enzymatic and
biochemical characteristics of recombinant hK8. Our data
indicate that hK8 may play a role in the degradation of
ECM proteins in the area surrounding the hK8-producing
cells, not only via its own activity but also through the activity
of the plasmin it produces by converting single-chain tPA to
two-chain tPA.References
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